Healthcare
Senseonics Holdings, Inc.(SENS)
Live Price
Offline$7.18
-2.05% today
1Y Change
-27.02%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $210.00M
- Revenue Growth
- +56.9%
- EPS Growth
- +33.6%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Senseonics Holdings, Inc. (SENS) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $7.18 and down 27.0% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +56.9%, EPS growth of +33.6%, a dividend yield of 0.0%. What stands out right now is revenue +56.9%, EPS +33.6%, free cash flow +3.9% with operating margin -184.9% and ROIC -66.6%. Valuation sits in the middle of the pack at price/sales 5.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SENS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+56.9% vs +7.6% peer median
Operating Margin
Below sector median
-184.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +56.9% and EPS at +33.6%, with operating margin around -184.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 18, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -0.9% | +5.8% | +23.4% |
2026 Mar 2, 2026 | -7.0% | -18.1% | -24.2% | -25.8% |
2025 Nov 5, 2025 | -30.3% | -7.6% | -2.1% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SENS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SENS Max Drawdown
-57.19%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SENS and SPY.
Company Overview
Senseonics Holdings, Inc.
NASDAQ Global Select
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
- Leadership
- Timothy T. Goodnow
- IPO Date
- Dec 22, 2015
- Employees
- 117
- Street Address
- 20451 Seneca Meadows Parkway
- Mailing
- Germantown, MD, 20876-7005
- Region
- Germantown, MD, US
- Reporting Currency
- USD
- Investor Line
- 301 515 7260
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.8
- Price/Book
- 3.5
Growth
- Revenue
- +56.9%
- EPS
- +33.6%
- Free Cash Flow
- +3.9%
Profitability
- Gross Margin
- 45.0%
- Operating Margin
- -184.9%
- Net Margin
- -189.9%
- ROE
- -104.2%
- ROIC
- -66.6%
Balance Sheet
- Debt/Equity
- 0.68
- Current Ratio
- 4.83
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.